logo
Share SHARE
FONT-SIZE Plus   Neg

4SC's Anti-Cancer Drug Resminostat Achieves Median Overall Survival Of 8 Months

4SC AG (FSCGF.PK) announced the publication of convincing overall survival data from a Phase II study with its lead anti-cancer drug resminostat applied as a novel combination therapy approach with sorafenib in second-line advanced liver cancer at the 2012 annual meeting of the International Liver Cancer Association in Berlin, Germany, on September 16, 2012. The international, open-label, two-arm SHELTER trial enrolled patients with advanced liver cancer who had demonstrated proven radiological tumor progression under first-line therapy with the cancer drug sorafenib.

The study investigated safety and efficacy of resminostat as a monotherapy and in combination with sorafenib in this patient group with currently no approved treatment option.

Final median overall survival of 8.0 months was determined in the resminostat/sorafenib combination 'intend-to-treat' population, i.e. all study patients who were treated with the combination of 600 mg resminostat total daily dose and 400 mg sorafenib TDD. According to the company, the data for the resminostat/sorafenib combination therapy showed a progression-free survival rate after 12 weeks of treatment of 70.0% and a median PFS of 4.7 months.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A California man has filed a lawsuit against McDonald's alleging that the fast food giant is defrauding customers by cramming its mozzarella sticks with filler instead of real cheese. Chris Howe is seeking at least $5 million in damages on behalf of consumers in 42 states and the District of Columbia. The... Jeep, the 4x4 vehicles, which has developed a strong bond with its masters, is aggressively on an expansion mode in its 75th anniversary year. Its fans have always been in love with the famous tag "Go Anywhere, Do Anything." Meat products maker Tyson Foods Inc. (TSN) reported a profit for the first-quarter that increased 49% from last year. It raised its profit outlook for fiscal year 2016 ,but it cut its annual sales guidance.
comments powered by Disqus
Follow RTT